1. Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab
- Author
-
Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ, Mepolizumab HES Study Group, Baccarani M, Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ, Mepolizumab HES Study Group [.., Baccarani M, and ]
- Subjects
medicine.medical_specialty ,Hypereosinophilic syndrome ,business.industry ,Hazard ratio ,General Medicine ,Placebo ,medicine.disease ,Gastroenterology ,Confidence interval ,law.invention ,Randomized controlled trial ,law ,Prednisone ,Internal medicine ,Immunology ,medicine ,Adverse effect ,business ,Mepolizumab ,medicine.drug - Abstract
The primary end point was reached in 84% of patients in the mepolizumab group, as compared with 43% of patients in the placebo group (hazard ratio, 2.90; 95% confidence interval [CI], 1.59 to 5.26; P
- Published
- 2008